JayTee2328Jun 11, 21 10:07 AM
Added 200 shares @ $2.80 ... PALISADE Phase 3 Program focused on acute treatment of anxiety in adults with Social Anxiety Disorder FDA Fast Track designation granted Topline results anticipated in mid-2022.
Open Trade
VTGNLong Stock
Entry comments: Owned previously .... sold @ 2.57... Analyst projection: Baird Starts VistaGen Therapeutics at Outperform With $9 Price Target.
Broker:Fidelity
| Date | Price | |
|---|---|---|
| Entry | 5/20/2021 | 2.65 |
- Total Views207
- Position Size500
Copy and paste the following into your page or blog. If using WordPress, you must paste this in the HTML tab only:
JayTee2328Apr 17, 23 11:18 AM
Still holding this trade, currently at $.4212 but making Progress on Phase 3 Trial of Anxiety nasal spray ... FDA ositive feedback
